title: DSR-98776, a novel selective mGlu5 receptor negative allosteric modulator with potent antidepressant and antimanic activity.
abstract: Modulation of monoaminergic systems has been the main stream of treatment for patients with mood disorders. However, recent evidence suggests that the glutamatergic system plays an important role in the pathophysiology of these disorders. This study pharmacologically characterized a structurally novel metabotropic glutamate 5 (mGlu5) receptor negative allosteric modulator, DSR-98776, and evaluated its effect on rodent models of depression and mania. First, DSR-98776 in vitro profile was assessed using intracellular calcium and radioligand binding assays. This compound showed dose-dependent inhibitory activity for mGlu5 receptors by binding to the same allosteric site as 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a known mGlu5 inhibitor. The in vivo therapeutic benefits of DSR-98776 were evaluated in common rodent models of depression and mania. In the rat forced swimming test, DSR-98776 (1-3mg/kg) significantly reduced rats immobility time after treatment for 7 consecutive days, while paroxetine (3 and 10mg/kg) required administration for 2 consecutive weeks to reduce rats immobility time. In the mouse forced swimming test, acute administration of DSR-98776 (10-30 mg/kg) significantly reduced immobility time. This effect was not influenced by 4-chloro-DL-phenylalanine methyl ester hydrochloride-induced 5-HT depletion. Finally, DSR-98776 (30 mg/kg) significantly decreased methamphetamine/chlordiazepoxide-induced hyperactivity in mice, which reflects this compound antimanic-like effect. These results indicate that DSR-98776 acts as an orally potent antidepressant and antimanic in rodent models and can be a promising therapeutic option for the treatment of a broad range of mood disorders with depressive and manic states.
authors.affiliation: Drug Development Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan. Electronic address: taro-kato@ds-pharma.co.jp.
authors.forename: Taro
authors.initials: T
authors.lastname: Kato
authors.affiliation: Research Planning & Intelligence, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Takata
authors.affiliation: Drug Development Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
authors.forename: Maiko
authors.initials: M
authors.lastname: Kitaichi
authors.affiliation: Innovative Drug Discovery Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
authors.forename: Momoe
authors.initials: M
authors.lastname: Kassai
authors.affiliation: Drug Development Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Inoue
authors.affiliation: Innovative Drug Discovery Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
authors.forename: Chihiro
authors.initials: C
authors.lastname: Ishikawa
authors.affiliation: Drug Development Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
authors.forename: Wataru
authors.initials: W
authors.lastname: Hirose
authors.affiliation: Innovative Drug Discovery Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
authors.forename: Kozo
authors.initials: K
authors.lastname: Yoshida
authors.affiliation: Drug Development Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
authors.forename: Isao
authors.initials: I
authors.lastname: Shimizu
mesh_terms: D000494:Allosteric Regulation / Q000187:drug effects; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018692:Antimanic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism; D002707:Chlordiazepoxide / Q000494:pharmacology; D004095:Dihydropyridines / Q000494:pharmacology* / Q000627:therapeutic use; D057809:HEK293 Cells; D006801:Humans; D042541:Intracellular Space / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology; D051379:Mice; D010080:Oxazoles / Q000494:pharmacology* / Q000627:therapeutic use; D011595:Psychomotor Agitation / Q000188:drug therapy / Q000209:etiology; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D064529:Receptor, Metabotropic Glutamate 5 / Q000378:metabolism*; D012701:Serotonin / Q000172:deficiency; D013550:Swimming
chemical_list: C517706:3-methoxy-5-pyridin-2-ylethynylpyridine; D000928:Antidepressive Agents; D018692:Antimanic Agents; C000604555:DSR-98776; D004095:Dihydropyridines; D010080:Oxazoles; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D012701:Serotonin; D008694:Methamphetamine; D002707:Chlordiazepoxide; D002118:Calcium
keywords: Bipolar disorder; Major depressive disorder; Mania; Negative allosteric modulator; mGlu(5) receptor